Turning the tide in lung cancer

Nature Biotechnology

Volumn 28, Issue 10, 2010, Pages 999-1002

  Allison, Malorye ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; MOTESANIB; TRASTUZUMAB; UNCLASSIFIED DRUG;

DRUG APPROVAL; GENE MUTATION; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; SHORT SURVEY;

BIOTECHNOLOGY; CLINICAL TRIALS AS TOPIC; DRUG INDUSTRY; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 77957932532     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1010-999     Document Type: Short Survey

References (13)

1. Chustecka, Z. Medscape Today, 7 June 2010. 〈http://www.medscape.com/ viewarticle/723075〉
2. Stinchcombe, T.E. & Govindan, R. Lancet Oncol. 11, 604-605 (2010).
3. Subramanian, J. et al. J. Thorac. Oncol. 5, 1116-1119 (2010).
4. AstraZeneca. IREssa Label Change Press Release (astraZeneca, London) (17 June 2005).
5. Polverino, A. et al. Cancer Res. 66, 8715-8721 (2006).
6. Bass, M.B. et al. J. Clin. Oncol. 28, 15s, suppl; abstr 3037 (2010).
7. Zhang, X. et al. J. Nucl. Med. 47, 113-121 (2006).
8. Gambhir, S.S. et al. PLoS Med. 5, 1287-1297 (2008).
9. Pao, W. et al. PLoS Med. 2, e73 (2005).
10. Allison, M. Nat. Biotechnol. 28, 383-384 (2010).
11. Lawson, M.H. et al. J. Thorac. Oncol. 5, 956-963 (2010).
12. Kornblau, S.M. et al. Clin. Cancer Res. 16, 3721-3733 (2010).
13. Rosen, D.B. et al. PLoS ONE 5, e12405 (2010).